David Kandzari reviews the Spyral-HTN On study results for control of hypertension using renal denervation

1,196 views

SPYRAL HTN-ON MED confirmed RDN’s blood pressure lowering effect, in patients prescribed BP medications, at 6-months1

  • 24-hour systolic ambulatory blood pressure (ABPM) decreased 9.0 mmHg in RDN patients (P<0.0001)
  • Office systolic blood pressure (OSBP) decreased 9.4 mmHg in RDN patients (P<0.0001)
  • RDN is always on and provides 24-hr blood pressure lowering, including  during “high-risk” periods2,3,4
  • RDN procedures with the Symplicity SpyralTM system continued to be safe, despite a more rigorous approach1 Zero major adverse events at 6-months
  • Ablations were performed in the renal branch and accessory arteries, as well as main renal artery
  • In previous research, BP reductions of the magnitude reported in SPYRAL HTN-ON MED have been associated with a >20% relative risk reduction of cardiovascular events5
  • The SPYRAL HTN Global Clinical Program continues with the ongoing OFF MED pivotal trial
     



Footnotes/References:
1Kandzari et al, PCR 2018
2The HTN-ON med 24-hr data showed that BP was reduced throughout the day and night at a 6-month endpoint
3Amodeo C, Blood Pressure Monit, 2014
4Boggia J, The Lancet, 2007
5Ettehad D et al.,  The Lancet, 2016


HTN:RDN
461 videos

Hypertension and Renal Denervation. This resource helps non-invasive cardiologists, hypertension specialists, general practitioners, and nephrologists understand the benefits of Renal Denervation...

Join the conversation

to comment